The Safety Rates Drug Report

Member Login
2004.Q1    2004.Q2    2004.Q3    2004.Q4    2005.Q1    2005.Q2    2005.Q3    2005.Q4    2006.Q1    2006.Q2    2006.Q3    2006.Q4    2007.Q1    2007.Q2    2007.Q3    2007.Q4    2008.Q1    2008.Q2    2008.Q3    2008.Q4    2009.Q1    2009.Q2    2009.Q3    2009.Q4    2010.Q1    2010.Q2    2010.Q3    2010.Q4    2011.Q1    2011.Q2    2011.Q3    2011.Q4    2012.Q1    2012.Q2    2012.Q3    2012.Q4    2013.Q1    2013.Q2    2013.Q3    2013.Q4    2014.Q1    2014.Q2    2014.Q3    2014.Q4    2015.Q1    2015.Q2    2015.Q3    2015.Q4    2016.Q1    2016.Q2    2016.Q3   

Drug     Injury     Quarter    

Person who experienced the adverse event (patient)

Event ID CASEID CASEVERSION I F COD EVENT DT MFR DT INIT FDA DT FDA DT REPT COD AUTH NUM MFR NUM MFR SNDR LIT REF AGE AGE COD AGE GRP GNDR COD E SUB WT WT COD REPT DT TO MFR OCCP COD REPORTER COUNTRY OCCR COUNTRY
124131584 12413158 4 F 20160208 20160722 20160527 20160725 EXP US-PFIZER INC-2016277068 PFIZER 19.00 YR F Y 56.60000 KG 20160725 OT US US

Drug(s) used by person

Event ID CASEID DRUG SEQ ROLE COD DRUGNAME PROD AI VAL VBM ROUTE DOSE VBM CUM DOSE CHR CUM DOSE UNIT DECHAL RECHAL LOT NUM EXP DT NDA NUM DOSE AMT DOSE UNIT DOSE FORM DOSE FREQ
124131584 12413158 1 PS SOMAVERT PEGVISOMANT 1 Subcutaneous 40 MG, 1X/DAY 1535.21106 MG Y 21106 40 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION QD
124131584 12413158 2 SS SOMAVERT PEGVISOMANT 1 Subcutaneous 20 MG, ALTERNATE DAY 1535.21106 MG Y 21106 20 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION QOD
124131584 12413158 3 SS SOMAVERT PEGVISOMANT 1 Subcutaneous 20 MG, 2X/WEEK (TWO INJECTIONS/WEEK) 1535.21106 MG Y 21106 20 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION BIW
124131584 12413158 4 SS SOMAVERT PEGVISOMANT 1 Subcutaneous 20 MG, 2X/WEEK (TWO INJECTIONS/WEEK) 1535.21106 MG Y 21106 20 MG POWDER AND SOLVENT FOR SOLUTION FOR INJECTION BIW
124131584 12413158 5 C DESMOPRESSIN DESMOPRESSIN 1 Oral UNK 0
124131584 12413158 6 C DESMOPRESSIN DESMOPRESSIN 1 Nasal UNK 0
124131584 12413158 7 C LEXAPRO ESCITALOPRAM OXALATE 1 Oral UNK 0
124131584 12413158 8 C LEVONORGESTREL AND ETHINYL ESTRADIOL ETHINYL ESTRADIOLLEVONORGESTREL 1 Oral UNK 0
124131584 12413158 9 C HYDROCORTISONE. HYDROCORTISONE 1 Oral UNK 0
124131584 12413158 10 C SYNTHROID LEVOTHYROXINE SODIUM 1 Oral UNK 0
124131584 12413158 11 C COD LIVER OIL COD LIVER OIL 1 Oral UNK 0
124131584 12413158 12 C VITAMIN D3 CHOLECALCIFEROL 1 Oral UNK 0
124131584 12413158 13 C LANREOTIDE LANREOTIDE 1 UNK 0
124131584 12413158 14 C CABERGOLINE. CABERGOLINE 1 UNK 0
124131584 12413158 15 C OCTREOTIDE. OCTREOTIDE 1 Subcutaneous UNK 0
124131584 12413158 16 C PROBIOTIC /06395501/ BIFIDOBACTERIUM ANIMALIS SUBSP. LACTIS 1 Oral UNK 0

Indications of drugs used

Event ID CASEID INDI DRUG SEQ INDI PT
124131584 12413158 1 Acromegaly
124131584 12413158 5 Type 1 diabetes mellitus
124131584 12413158 9 Adrenocorticotropic hormone deficiency
124131584 12413158 10 Primary hypothyroidism

Outcome of event

Event ID CASEID OUTC COD
124131584 12413158 HO

Reactions reported

Event ID CASEID DRUG REC ACT PT
124131584 12413158 Neoplasm recurrence
124131584 12413158 Pituitary tumour benign

Reporting Sources (this data is often not reported and may therefore be missing here)

no results found

Therapies reported

Event ID CASEID DSG DRUG SEQ START DT END DT DUR DUR COD
124131584 12413158 1 20150730 20150730 0
124131584 12413158 2 20150730 20151021 0
124131584 12413158 3 20151022 20160311 0
124131584 12413158 4 20160329 0
124131584 12413158 5 20151125 0
124131584 12413158 6 20151221 0
124131584 12413158 7 201509 0
124131584 12413158 8 201509 0
124131584 12413158 9 201509 20160316 0
124131584 12413158 10 20141223 0
124131584 12413158 11 20141222 20160315 0
124131584 12413158 12 20141219 0
124131584 12413158 13 201412 0
124131584 12413158 14 2014 0
124131584 12413158 15 20160208 0
124131584 12413158 16 20141222 0